首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

PHARMACOECONOMICS
ISSN：1170-7690

PHARMACOECONOMICS

PHARMACOECONOMICS
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：较慢,6-12周
新锐分区：医学2区
年发文量：103
影响因子：4.6
JCR分区：Q1

基本信息

《药物经济学》是一本基准期刊，发表关于药物经济学和生活质量评估在优化药物治疗和健康结局方面的应用的同行评议、权威和实用文章。为医疗保健决策者提供应用药物经济学原创研究和教育材料的无价来源。药物经济学致力于与患者护理和药物利用相关的复杂药物经济学问题的清晰沟通。药物经济学提供了一系列额外的功能，旨在增加期刊内容的可见性、读者群和教育价值。每篇文章都附有一个要点摘要，为广大读者提供了一个省时的内容概述。文章可能附有简明扼要的语言摘要，以帮助读者了解该领域的一些知识，但不是深入的专业知识，以理解文章的科学内容和整体含义。
1170-7690SCIE/SSCI/Scopus收录
4.6
点击查看最新影响趋势>
4.5
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学2区
ECONOMICS 经济学
2区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务
2区
HEALTH POLICY & SERVICES 卫生政策与服务
1区
PHARMACOLOGY & PHARMACY 药学
1区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：ECONOMICS
SSCI
Q1
58/620
学科：HEALTH CARE SCIENCES & SERVICES
SCIE
Q1
20/188
学科：HEALTH POLICY & SERVICES
SSCI
Q1
7/125
学科：PHARMACOLOGY & PHARMACY
SCIE
Q1
57/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：ECONOMICS
SSCI
Q1
86/620
学科：HEALTH CARE SCIENCES & SERVICES
SCIE
Q1
24/188
学科：HEALTH POLICY & SERVICES
SSCI
Q1
11/125
学科：PHARMACOLOGY & PHARMACY
SCIE
Q1
42/353
91
103
点击查看年发文量趋势图>
1%0较慢,6-12周-医学-药学
13%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
80.58%63.92%6.19%
CiteScore：8.10
SJR：1.880
SNIP：1.730
学科类别分区排名百分位
大类：Medicine
小类：Health Policy
Q1
17 / 320
大类：Medicine
小类：Public Health, Environmental and Occupational Health
Q1
57 / 687
大类：Medicine
小类：Pharmacology
Q1
60 / 321

期刊高被引文献

Spillover Effects on Caregivers’ and Family Members’ Utility: A Systematic Review of the Literature
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00768-7
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00806-4
Transparency in Decision Modelling: What, Why, Who and How?
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00819-z
Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00774-9
Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00800-w
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00788-3
Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00782-9
Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00775-8
Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00781-w
Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00851-z
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00825-1
Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00845-x
Comment on “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00802-8
Close-Person Spill-Overs in End-of-Life Care: Using Hierarchical Mapping to Identify Whose Outcomes to Include in Economic Evaluations
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00786-5
Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00855-9
TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00844-y
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00839-9
Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00834-0
Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00848-8
Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00862-w
Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00863-9
One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00869-3
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00870-w
Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00875-5
Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00815-3
Cooking Up a Transparent Model Following a DICE Recipe
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00840-2
Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00766-9
Mapping the PedsQL™ onto the CHU9D: An Assessment of External Validity in a Large Community-Based Sample
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00808-2
A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator’s Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00798-1
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00841-1
Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00783-8
Improving Transparency in Decision Models: Current Issues and Potential Solutions
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00850-0
The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00847-9
How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00853-x
来源期刊：DOI：
来源期刊：DOI：
来源期刊：DOI：
来源期刊：DOI：
来源期刊：DOI：
来源期刊：DOI：
Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00767-8
Correction to: Publication of Decision Model Source Code: Attitudes of Health Economics Authors
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00813-5
Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00874-6
Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00857-7
Correction to: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00776-7
Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00835-z
Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00861-x
Transferability of Economic Evaluations of Treatments for Advanced Melanoma
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00860-y
Correction to: Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities
来源期刊：PharmacoeconomicsDOI：10.1007/s40273-019-00778-5
Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013
来源期刊：PharmacoEconomicsDOI：10.1007/s40273-019-00821-5

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

ACADEMIC EMERGENCY MEDICINE封面

ACADEMIC EMERGENCY MEDICINE

学科领域：医学
影响因子：3.2
中科院分区： 2区
ACADEMIC RADIOLOGY封面

ACADEMIC RADIOLOGY

学科领域：医学
影响因子：3.9
中科院分区： 2区
APPETITE封面

APPETITE

学科领域：医学
影响因子：3.8
中科院分区： 2区
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA封面

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA

学科领域：医学
影响因子：3.1
中科院分区： 2区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布
大类学科小类学科Top期刊综述期刊
医学2区
ECONOMICS 经济学
2区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务
2区
HEALTH POLICY & SERVICES 卫生政策与服务
1区
PHARMACOLOGY & PHARMACY 药学
1区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
2区
ECONOMICS 经济学
3区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务
3区
HEALTH POLICY & SERVICES 卫生政策与服务
3区
否
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学3区
ECONOMICS 经济学
3区
HEALTH CARE SCIENCES & SERVICES 卫生保健与服务
3区
HEALTH POLICY & SERVICES 卫生政策与服务
3区
PHARMACOLOGY & PHARMACY 药学
3区
否
否